Interroll (INRN) H1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2026 earnings summary
31 Jul, 2026Executive summary
Order intake increased by 3.9% year-over-year to CHF 295.2 million (+8.5% in local currency), with strong growth in Asia-Pacific and EMEA, while Americas stabilized and North America is expected to improve in H2.
Sales grew 9.0% year-over-year to CHF 269.9 million (+14.1% in local currency), reflecting solid demand and strategic execution across most regions and product lines.
EBIT declined by 2.2% to CHF 27.0 million (10.0% margin), mainly due to higher investments in innovation, acquisition costs, and amortization.
Net profit was CHF 19.8 million (margin 7.3%), down 6.6% year-over-year, impacted by higher tax expenses and one-off effects.
Integration of Royal Apollo and Sortteq expanded product offerings and service capabilities, especially in spiral conveyor technology and sortation.
Financial highlights
EBITDA rose 3.4% year-over-year to CHF 39.9 million (margin 14.8%).
Operating cash flow surged 80.7% to CHF 39.4 million, driven by working capital improvements.
Free cash flow was negative at CHF -19.4 million due to acquisition-related outflows.
Total assets rose to CHF 686 million, mainly due to acquisitions and continued investments.
Net cash position at end of June was CHF 172 million, reflecting strong financial resilience despite acquisition outflows.
Outlook and guidance
Business momentum is expected to continue improving in H2, with Americas sales reorganization and Royal Apollo integration supporting growth.
No formal quantitative guidance provided, but management expects continued positive momentum and normalization of tax rate.
CapEx will be higher than usual, above CHF 20 million, due to productivity and new product ramp-up.
Long-term growth drivers include automation, digitalization, and labor shortages.
Latest events from Interroll
- Order intake rose 5% and EBITDA margin reached 18.3%, with stable dividend proposed.INRN
H2 2025 - Stable sales and order intake, with margin pressure but strong project and regional momentum.INRN
H1 2025 - EBIT, EBITDA, and net result rose despite lower sales, with EMEA leading recovery.INRN
H1 2024 - Order intake steady, sales down, robust margins; dividend unchanged, 2025 a transition year.INRN
H2 2024